

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
4 January 2018 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- Administrative Meeting (BAP members only @ 7:30 AM-9:00 AM)
- Sign-In
- Welcome and Opening Remarks
- Public Citizen Comments
- Therapeutic Class Reviews

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drugs/drug classes during the November 2017 meeting:

- *Drug Class Reviews*
 - *Weight Loss Agents for Obesity*
 - *Oncology Agents—Multiple Myeloma Subclass*
 - *Vitamins—Prenatal Vitamins Subclass*
- *Newly-Approved Drugs per CFR 199.21(g)(5)*
 - *abemaciclib (Verzenio) – Oral Oncology Agents for Breast Cancer*
 - *amantadine ER (Gocovri) – Parkinson’s Disease Drugs*
 - *belimumab (Benlysta) – Immunosuppressive Agents – Systemic Lupus Erythematosus*
 - *betrixaban (Bevyxxa) – Oral Anticoagulants*
 - *plasma-derived human C1 esterase inhibitor SQ injection(Haegarda) Hereditary Angioedema*
 - *delafloxacin (Baxdela) – Antibiotics – Quinolones*
 - *enasidenib (Idhifa) – Oral Oncology Agents for Acute Myelogenous Leukemia*
 - *fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) – Pulmonary II Combination Agents – Chronic Obstructive Pulmonary Disease*
 - *fluticasone propionate (ArmonAir RespiClick) – Pulmonary I Agents – Inhaled Corticosteroids*

- *glecaprevir/pibrentasvir (Mavyret) – Hepatitis C Virus Direct Acting Antivirals (HCV DAAs)*
- *guselkumab (Tremfya) injection – Targeted Immunomodulatory Biologics (TIBs)*
- *insulin aspart (Fiasp) – Insulins – Short-Acting Agents*
- *L-glutamine (Endari) oral powder – Dietary Supplements*
- *naldemedine (Symproic) – Gastrointestinal-2 Agents – Opioid Induced Constipation (OIC) Drugs*
- *lesinurad/allopurinol (Duzallo) – Antigout Agents – Chronic*
- *methylphenidate ER orally dissolving tablet (Cotempla XR ODT) – Attention Deficit Hyperactivity Disorder (ADHD) Drugs*
- *neratinib (Nerlynx) – Oral Oncology Agents for Breast Cancer*
- *nitisinone (Nityr) – Metabolic Replacement Agents*
- *perampanel (Fycompa oral solution) – Anticonvulsants/Anti-Mania Agents*
- *simvastatin oral suspension (FloLipid) – Antilipidemic-Is*
- *sofosbuvir/velpatasvir/voxilaprevir (Vosevi) – HCV DAAs*
- *Utilization Management Issues*
 - *Prior Authorization Criteria—New Criteria*
 - *Antidepressants and Non-Opioid Pain Syndrome Agents—Bupropion hydrobromide (Aplenzin)*
 - *Prior Authorization Criteria—Updated Criteria*
 - *Oral Oncological Agents: Dabrafenib (Tafinlar) and Trametinib (Mekinist)*
 - *Oral Oncological Agents: Vemurafenib (Zelboraf)*
 - *Targeted Immunomodulatory Biologics (TIBs): Ustekinumab (Stelara)*
 - *Corticosteroids—Immune Modulators—Atopic Dermatitis Subclass: Crisaborole (Eucrisa)*
 - *Corticosteroids—Immune Modulators—Hereditary Angioedema (HAE) Subclass: Plasma-derived C1 Esterase Inhibitor IV (Cinryze)*
 - *Non-Insulin Diabetes Drugs: GLP1RAs—Step Therapy, Manual PA Criteria, and MN Criteria*
- *Brand Over Generic Authorization for Mesalamine Delayed Release (Lialda): Prior Authorization and Co-pay Change*
- *Re-evaluation of Generic Nonformulary Medications*

- *ADHD/Wakefulness Promoting Drugs: Wakefulness Promoting Drugs Subclass:*
 - *armodafinil (Nuvigil); modafinil (Provigil): UF status and PA criteria*
 - *sodium oxybate (Xyrem) updated PA criteria*
- *BPH Agents: 5-Alpha Reductase Inhibitors (5-ARI) Subclass*
 - *dutasteride (Avodart) UF status*
- *Renin-Angiotensin Antihypertensives*
 - *irbesartan (Avapro), irbesartan/HCTZ (Avalide) step therapy status*

➤ **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.